Eli Lilly clears a major legal hurdle in its Centessa deal after UK High Court approval

Eli Lilly has received approval from the High Court of Justice of England and Wales for its acquisition of Centessa Pharmaceuticals plc, according to a business report published June 22, 2026.

Centessa, listed on the Nasdaq under the ticker CNTA, is described in the report as a clinical-stage company developing a new class of medicines focused on the treatment of excessive daytime sleepiness. The company’s work is positioned in the report as part of an emerging approach to sleep-related disorders, areas where Lilly has broader pharmaceutical interests but where Centessa’s early-stage programs are meant to add incremental scientific and clinical depth.

For Lilly, a court sanction is a critical procedural step in completing certain types of UK restructurings and deal mechanisms. The High Court approval indicates that the transaction has passed a key legal review in England and Wales, reducing one of the remaining uncertainties that can slow merger timelines.

The approval comes as drugmakers increasingly use acquisitions to add late-breaking clinical candidates rather than relying solely on internal discovery. Clinical-stage companies like Centessa can offer platforms or therapeutic candidates that, if they progress, may broaden a buyer’s ability to compete in therapeutic categories that have growing demand or clear clinical endpoints.

Market participants typically watch UK court approvals closely because they can be a gating item for closing, particularly in cross-border transactions that require shareholder and regulatory steps across jurisdictions. While this approval addresses a major legal checkpoint, it does not by itself guarantee that all remaining conditions for closing have been satisfied.

Centessa’s focus on excessive daytime sleepiness is also notable because it targets a symptom-driven clinical area with meaningful patient impact. Drug developers in sleep-related indications often face intense scrutiny around efficacy, tolerability, and trial design, since patient heterogeneity can affect outcomes.

At this point, the court approval is the clearest reported milestone. The broader timeline for deal completion, including any remaining approvals or documentation steps, was not detailed in the published report referenced in this article.

What to watch next is whether the parties can move from court-sanctioned approval to final completion steps, and whether additional communications clarify the next expected milestone dates. Companies and investors will also look for any follow-on disclosures tied to integration planning and how Centessa’s development programs will be slotted into Lilly’s broader pipeline strategy.